NYSEAMERICAN:CPHI - China Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.3201 -0.01 (-3.03 %)
(As of 11/18/2018 01:08 PM ET)
Previous Close$0.3201
Today's Range$0.30 - $0.34
52-Week Range$0.16 - $1.45
Volume438,933 shs
Average Volume832,576 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, cephalosporin oral solutions, and granules. The company's products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.

Receive CPHI News and Ratings via Email

Sign-up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CPHI
Previous SymbolNYSEMKT:CPHI
CUSIPN/A
Phone+86-898-66811730

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees276
Outstanding Shares43,580,000
Market Cap$0.00
OptionableNot Optionable

China Pharma (NYSEAMERICAN:CPHI) Frequently Asked Questions

What is China Pharma's stock symbol?

China Pharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CPHI."

How were China Pharma's earnings last quarter?

China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI) announced its earnings results on Thursday, November, 15th. The company reported ($0.04) EPS for the quarter. The company earned $2.30 million during the quarter. View China Pharma's Earnings History.

When is China Pharma's next earnings date?

China Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for China Pharma.

Has China Pharma been receiving favorable news coverage?

News headlines about CPHI stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. China Pharma earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Are investors shorting China Pharma?

China Pharma saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 274,753 shares, an increase of 52.5% from the September 28th total of 180,158 shares. Based on an average daily volume of 420,158 shares, the short-interest ratio is currently 0.7 days. Approximately 1.3% of the shares of the stock are sold short. View China Pharma's Current Options Chain.

Who are some of China Pharma's key competitors?

Who are China Pharma's key executives?

China Pharma's management team includes the folowing people:
  • Ms. Zhilin Li, Pres, CEO, Chairman & Interim CFO (Age 65)
  • Ms. Yao Huang, Chief Technical Officer
  • Ms. Jian Yang, Sec. (Age 58)

How do I buy shares of China Pharma?

Shares of CPHI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is China Pharma's stock price today?

One share of CPHI stock can currently be purchased for approximately $0.3201.

What is China Pharma's official website?

The official website for China Pharma is http://www.chinapharmaholdings.com.

How can I contact China Pharma?

China Pharma's mailing address is 2Nd Floor, No. 17, Jinpan Road, Haikou, HAIKOU, HAN 570216, China. The company can be reached via phone at +86-898-66811730.


MarketBeat Community Rating for China Pharma (NYSEAMERICAN CPHI)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  187
MarketBeat's community ratings are surveys of what our community members think about China Pharma and other stocks. Vote "Outperform" if you believe CPHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPHI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Featured Article: Fiduciary

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel